INTRODUCTION
Persistent human papillomavirus (HPV) accounts for nearly all cervical cancers as well as 91% of anal cancers, 70% of oropharyngeal cancers, and 60% to 75% of other genital cancers (penile, vaginal, and vulvar cancers). 1 The majority of HPV-attributable cancers can be prevented through human papillomavirus vaccination (HPVV). 2 Several public health organizations began recommending the HPV vaccine in 2007. [3] [4] [5] The current Advisory Committee on Immunization Practices and the American Cancer Society recommendations, updated in 2016-2017, endorse routine HPVV at an age of 11 or 12 years for both males and females. 6, 7 A catch-up vaccination is recommended for people up to 26 years. For adolescents starting the vaccine before the age of 15 years, a 2-dose schedule is recommended, and 3 doses are recommended for those initiating vaccination after the age of 15 years. 6, 7 Despite the recommendations, in 2016, only 65.1% of females and 56.0% of males aged 13 to 17 years nationally had initiated HPVV (1 or more doses), and 49.5% of females and 37.5% of males of the same age were up to date (UTD) with the current recommendations (2-3 doses). 8 These estimates of vaccine uptake are well below the Healthy People 2020 target that 80% of vaccine-eligible adolescents will be UTD 9 and the American Cancer Society's goal that by 2026, 80% of adolescents will be UTD with HPVV before their 13th birthday. 10 Previous investigations have identified subpopulations with lower vaccination rates, including younger adolescents, males, and non-Hispanic (NH) whites. 8, 11, 12 Vaccination rates also widely vary by state and geographic region, with the uptake substantially lower in rural areas than urban areas. 8 However, the number of additional adolescents aged 11 to 12 years who need to be vaccinated for established public health targets to be reached is unknown. Furthermore, the characteristics of those adolescents who have
Cancer December 15, 2018 not initiated or completed vaccination are also unknown but could help to inform programs aimed at increasing vaccination coverage. In the current study, we estimated the number of adolescents (11-12 years old) who would need to receive 1 and 2 doses of the HPV vaccine for 80% prevalence to be reached by 2026 nationwide. We also examined the characteristics of adolescents who did not initiate vaccination and were not UTD by their 13th birthday.
MATERIALS AND METHODS
The study used de-identified and publicly available data and exempt from institutional review board approval and informed consent. The 2016 National Immunization Survey for Teens (NIS-Teen) was used to estimate sexspecific HPVV utilization. NIS-Teen is a dual-frame (landline and cellular) telephone survey of parents and guardians of teens aged 13 to 17 years designed to estimate population-based vaccination coverage. 13 During interviews, parents were asked questions about sociodemographic factors and health care utilization (provider visits and vaccination history). Parents were also asked for consent to contact their adolescent's health care provider(s) to verify the receipt of vaccination (types, doses, and dates given, including those before the age of 13 years). We restricted our analyses to those with verified vaccination data in accordance with previous reports. 8 Overall, 53.9% and 47.9% of landline and cell phone participants had provider data, respectively. We selected a total of 4209 respondents (2202 males and 2007 females) surveyed in 2016 with provider-verified data who were 13 years old at the time of the interview to estimate HPVV uptake. Only adolescents who were 13 years old were included because the inclusion of interviewees who were 14 to 17 years old in 2016 would reflect patterns in older birth cohorts and reduce the accuracy of recent HPVV utilization estimates. US Census Bureau projections were used to estimate the number of people aged 11 to 12 years between 2018 and 2026 nationwide.
Outcome and Statistical Analyses
We examined the sex-specific prevalence of HPVV initiation (the receipt of 1 or more doses) and those who were UTD (the receipt of 2 or more doses) by the age of 13 years in the 2016 NIS-Teen survey.
We computed future initiation and UTD vaccination prevalence by assuming linear growth between these 2016 sex-specific baseline HPVV rates and 2026 to eventually achieve 80% prevalence. For example, according to 2016 NIS-Teen data, 35.5% of females were UTD before their 13th birthday, and by 2018, 2020, 2022, 2024, and 2026, target prevalences of 44.4%, 53.3%, 62.2%, 71.1%, and 80%, respectively, were set to reach the final goal of 80% by 2026, as shown in Figure S1A . For males, the 2016 baseline UTD HPVV prevalence from NIS-Teen was 31.1%, and by 2018, 2020, 2022, 2024, and 2026, target prevalences of 40.9%, 50.7%, 60.4%, 70.2%, and 80%, respectively, were set to reach the final goal of 80% by 2026, as shown in Figure S1B . Linear growth rates were similarly applied to HPVV initiation (Fig. S1A,B) .
We estimated the number of additional adolescents who would need to be vaccinated by subtracting the number of adolescents who had at least 2 doses of the HPV vaccine (using the census population projections and recent NIS-Teen vaccination estimates) from the total number of adolescents who would need to be vaccinated to reach the previously described target prevalence of HPVV within a given year (using census population projections and assuming a targeted vaccination prevalence) with formula 1, which shows the sex-and yearspecific number of adolescents who would need to receive 2 doses of the HPV vaccine for the targeted prevalence to be reached:
where NNV s,y is the number of 11-to 12-year-olds in sex (s)-and year (y)-specific populations needing to receive 2 or more doses of the vaccine for the targeted prevalence to be reached, Pop s,y is the sex (s)-and year (y)-specific population of 11-to 12-year-olds from US Census data, HPVVT s,y is the sex (s)-and year (y)-specific target prevalence of adolescents receiving 2 doses of the HPV vaccine by the age of 13 years, HPVVB s is the baseline sex (s)-specific HPVV estimate of adolescents receiving 2 or more doses of the HPV vaccine by the age of 13 years according to 2016 NIS-Teen data, s is the sex (male or female), and y is the year (2018-2026).
The number of additional adolescents who would need to initiate the HPVV was similarly calculated with formula 2, which shows the sex-and year-specific number of adolescents who would need to receive 1 dose of the HPV vaccine for the targeted prevalence to be reached within a given year:
where NNVI s,y is the number of adolescents aged 11 to 12 years in sex (s)-and year (y)-specific populations Cancer December 15, 2018 needing to initiate the vaccination for the targeted prevalence to be reached, Pop s,y is the sex (s)-and year (y)-specific population of 11-to 12-year-olds from US Census data, HPVVTI s is the sex (s)-and year (y)-specific target percentage of adolescents receiving 1 dose of the HPV vaccine by the age of 13 years, HPVVBI s is the baseline sex (s)-specific estimated percentage of adolescents receiving 1 or more doses of the HPV vaccine by the age of 13 years according to 2016 NIS-Teen data, s is the sex (male or female), and y is the year (2018-2026).
The product term approach shown in formulas 1 and 2 is similar to what we previously used to estimate the number of people who need to be screened for colorectal cancer to reach nationwide goals. 14 The number of adolescents needing to achieve 80% vaccination prevalence by 2026 was computed by summing the number of adolescents in need of vaccination in each cohort of 11-12-year-old adolescents during 2018-2026. We considered that a new cohort of 11-to 12-year-olds would enter the vaccine-eligible population every other year, so the cumulative number of adolescents in need of HPVV was summed across the following years: 2018, 2020, 2022, 2024, and 2026. We calculated confidence intervals (CIs) for the number needing vaccination by multiplying CIs of HPVV prevalence estimates, which were computed with Taylor series approximation, with census projection population counts.
The number of doses needed to achieve 80% UTD prevalence by 2026 was calculated by the multiplication of census population estimates by biennial HPVV prevalence targets (described previously) and then by 2 because 2 doses are recommended by the age of 13 years. We used formula 3, which shows the number of total doses that would need to be administered for 80% UTD HPVV prevalence to be reached:
where Pop sy is the sex (s)-and year (y)-specific population of 11-to 12-year-olds and HPVVT s,y is the sex (s)-and year (y)-specific target prevalence of adolescents receiving 2 or more doses of the HPV vaccine.
We also calculated the number of additional HPVV doses that would need to be administered to achieve 80% prevalence by subtracting the number who would be receiving 1 or 2 doses given the 2016 HPVV prevalence from the total number of doses needed to achieve the annual HPVV prevalence targets. We used formula 4, which shows the number of additional doses that would need to be administered for 80% HPVV prevalence to be reached:
where Pop sy is the sex (s)-and year (y)-specific population of 11-to 12-year-olds, HPVVT s,y is the sex (s)-and year (y)-specific target prevalence of adolescents receiving 2 or more doses of the HPV vaccine, HPVV2 s is the sex (s)-specific HPVV estimate of adolescents receiving 2 or more doses of the HPV vaccine by the age of 13 years according to 2016 NIS-Teen data, HPVV1 s is the sex (s)-specific HPVV estimate of adolescents receiving 1 dose of the HPV vaccine by the age of 13 years according to 2016 NIS-Teen data, s is the sex (male or female), and y is the year (2018-2026). We calculated cumulative doses by summing across the following years: 2018, 2020, 2022, 2024, and 2026.
To characterize those in need of HPVV, we examined the distribution of sociodemographic and health care factors of adolescents who were not UTD by the age of 13 years with 2016 NIS-Teen data, and we compared them with those who were UTD with chi-square tests. The prevalence of initiation among those who were UTD with HPVV were also examined. All statistical tests were conducted with SAS 9.4 or SAS-callable SUDAAN 9.0.3 and accounted for NIS-Teen's complex survey design. Survey data were also weighted to adjust for nonresponse. 13 
RESULTS
In 2018, there were approximately 4.10 million females and 4.29 million males aged 11 to 12 years residing in the United States. These numbers are projected to grow modestly to 4.31 million and 4.55 million by 2026, respectively. On the basis of NIS-Teen data, 50.4% of adolescents aged 11 to 12 years were male, 23.4% were Hispanic, 52.7% were NH white, and 13.6% were NH black (Table 1) .
HPVV Initiation
According to 2016 NIS-Teen survey data, approximately 48.9% of females and 44.3% of males had initiated HPVV by the age of 13 years (Table 2) . To achieve 80% prevalence of HPVV initiation by 2026, an additional 3.95 million females (95% CI, 3.14 million to 4.76 million) and an additional 4.78 million males (95% CI, 3.91 million to 5.64 million), 11 to 12 years old, would need to initiate vaccination. In 2018, an additional 253,252 females and an additional 304,573 males would need to initiate HPVV for the intermediate targets of 55.1% and 51.4%, respectively, to be reached. In 2026 alone, an additional 1.34 million females and an additional 1.63 million males would need to be vaccinated for 80% prevalence to be achieved. The increases in the number needing HPVV over the study period largely reflect the increasing proportion of adolescents who would need to be vaccinated for the eventual goal of 80% prevalence to be reached, rather than population growth.
UTD HPVV
In 2016, 35.5% of females and 31.5% of males were UTD with the HPV vaccine by their 13th birthday (Table 3) . For 80% UTD HPVV prevalence to be achieved by 2026, an additional 6.77 million females and 7.62 million males would need to receive 2 doses of the vaccine Cancer December 15, 2018 ( Table 3) . Most adolescents (80.3%) who were not UTD with the HPV vaccine by their 13th birthday had not yet initiated the HPV vaccine (Table 1) . Thus, the females and males aged 11 to 12 years who would need 2 doses of the HPV vaccine for 80% prevalence to be achieved are mostly those who would also need to initiate the vaccine.
Number of HPVV Doses
A total of 57.62 million doses would need to be administered to adolescents 11 to 12 years old for 80% prevalence of UTD HPVV to be achieved by 2026, and 18.27 million of those doses represent the additional number needed beyond current vaccination levels for 80% prevalence to be achieved (Fig. 1A,B) .
Characteristics of Those in Need of HPVV
Characteristics according to the UTD HPVV status, based on 2016 NIS-Teen data, are presented in Table 1 . Disproportionate percentages of males, whites, and privately insured adolescents were not UTD with recommended HPVV by the age of 13 years. Among those who were not UTD with the HPVV before their 13th birthday, the large majority had a wellness checkup between the ages of 11 and 12 years (>90%), 51.9% were male, 56.7% were NH white, and 20.8% were Hispanic. Most lived in households above the poverty level (80.4%) and had mothers with more than 12 years of education. An assessment of the insurance status indicated that the largest proportion of adolescents who had not initiated HPVV had private insurance (56.5%), which was followed by Medicaid (34.9%); less than 5% were uninsured. The patterns of adolescents who had not initiated HPVV were similar (Table S1) .
DISCUSSION
In 2016, only 35.5% of females and 31.1% of males were UTD with HPVV before their 13th birthday. We estimated that an additional 6.77 million girls and an additional 7.62 million boys aged 11 to 12 years would need to receive 2 doses of the vaccine between 2018 and 2026 for 80% prevalence to be achieved by 2026. Most adolescents who were not UTD with the HPV vaccine had not initiated the HPV vaccine series and had an 11-to 12-year wellness checkup, were privately insured, and lived in households above the poverty level. Population growth Cancer December 15, 2018 contributed minimally to the number needing vaccination in future birth cohorts. We observed that a large number of adolescents would need to initiate HPVV and receive the second dose of the HPV vaccine for 80% prevalence to be achieved by 2026. Current strategies to increase HPVV in the United States focus on improving provider recommendations and parental acceptability of HPVV because these factors are strongly related to utilization [15] [16] [17] [18] and were recommended by the President's Cancer Panel and the National Vaccine Advisory Committee. 19, 20 In our study, more than 90% of adolescents who had not initiated HPVV by their 13th birthday had an 11-to 12-year-old wellness visit, and this highlights that most adolescents presumably had an opportunity to be vaccinated during this timeframe. We could not ascertain whether a provider recommendation was given during these visits; however, only 55% of parents reported that they had ever received a recommendation to vaccinate their child against HPV, and previous studies show that opportunities to endorse and administer HPVV during clinical visits are often missed. [21] [22] [23] [24] [25] Providers cite several barriers to recommending HPVV, including incomplete knowledge of the vaccine's benefits, parental hesitancy, and anticipated parental refusal or deferment, and some providers base recommendations on perceived risk. 22, [26] [27] [28] [29] These barriers may be particularly prominent in our study population because some providers may anticipate greater parental refusal and discomfort with discussing a sexually transmitted infection in younger patients, and others may not be aware of the recommended age for initiating the vaccine. 21, 22, 30 In a survey of family practitioners and pediatricians, 35% always recommended HPVV to their patients aged 11 to 12 years, whereas 50% did so to patients aged 18 to 26 years. 21 Some providers cite concerns about the financial burden to families or insurance reimbursement for not recommending the vaccine, 28, 29 although cost is not a frequently named barrier among parents. 27, 31 Parents most commonly identify a lack of provider recommendations, awareness, and knowledge as reasons for not vaccinating their children, and younger adolescent age is also related to parental refusal and delay of HPVV. 17, [31] [32] [33] Our findings and others suggest that broader implementation of evidence-based approaches is needed to improve uptake among unvaccinated adolescents. 19, 34, 35 Several provider-and system-focused interventions have been shown to be effective at increasing HPVV rates in the clinical setting. [36] [37] [38] [39] For example, HPVV rates improved in federally qualified health centers that implemented multicomponent interventions, including provider training, 38 and in primary care clinics where providers received communication training. 39 In addition, parental text-message and mailed reminders as well as in-clinic provider electronic reminders may boost vaccination rates, and repeated physician recommendations may be needed to convince parents who initially refuse. 35, 40 Furthermore, a recent study found that parents viewed cancer prevention as the most persuasive reason for vaccinating their children, and such information could be incorporated into provider communication strategies and parental educational materials targeting unvaccinated adoloscents. 41 Other countries, including Portugal, England, and Australia, have achieved HPVV initiation rates of 80% or higher with large-scale and population-based approaches, including school-based programs. [42] [43] [44] In the United States, there are some federal and state-based initiatives aimed at improving vaccination rates. The federally funded Vaccines for Children program provides free vaccines for low-income children. 45 Approximately 50% of children younger than 19 years are eligible to receive vaccines through Vaccines for Children, and this program likely contributes to the counterintuitive higher HPVV utilization rate in Medicaid-insured adolescents versus privately insured adolescents in our study as well as others. 18, 46, 47 For privately insured adolescents, the current Affordable Care Act requires that most insurers cover HPVV without cost sharing; the influence of this provision on HPVV rates among adolescents has not been examined, although it may be related to recent vaccination increases in rates among women aged 18 to 25 years. 48 State-based school-entry requirements for other vaccines (eg, diphtheria and varicella) have been effective in achieving high (~95%) vaccination rates for these respective diseases, although such requirements for HPVV are controversial; parental support is ambiguous, and a positive impact on HPVV utilization has yet to be seen. [49] [50] [51] [52] In the United States, the impact of voluntary and mandated school-based initiatives is unclear. 53, 54 In 2008, Virginia and Washington, DC enacted school entry requirements, but it is unclear whether these requirements are related to HPVV utilization because of the existence of broad vaccination optouts. 49 In 2015, Rhode Island enacted stricter legislation (without philosophical optouts) and had the highest rates of HPVV initiation in the nation as of 2016, although HPVV rates were relatively high before the legislation. 8, 55 An additional recommended strategy for improving HPVV rates is to expand access to vaccines outside Cancer December 15, 2018 the medical home, including schools, health department clinics, pharmacies, and urgent-care settings. 19, [56] [57] [58] A considerable proportion of parents report a willingness to have their children receive HPVV in nontraditional settings. 56, 59 However, barriers remain. For example, one challenge of administering HPVV in pharmacies is restrictive policies; some states do not allow pharmacists to provide HPVV to people younger than 19 years, and others require a prescription from a physician. 58, 60 Concerns over in-network insurance coverage for vaccines given in pharmacies have also been raised. 58, 60 Other obstacles for rolling out large-scale vaccinations in nontraditional settings, such as schools, include overcoming administrative hurdles, obtaining local school board approval, and collecting parental consent forms. 58 Several assumptions and limitations of our study may influence the interpretation of the results. The number of additional adolescents who need to be vaccinated for 80% prevalence to be achieved is a function on how this goal is achieved. We assumed linear growth between 2016 and 2026 to achieve the eventual target prevalence of 80%, which may or may not occur during this timeframe. Furthermore, if 80% HPVV prevalence is obtained earlier or later than 2026, then our estimates may be lower or higher than what will be seen in the future. In addition, nonresponse to the NIS-Teen survey and a lack of provider data (which was mostly due to an absence of consent) may introduce selection bias. The HPVV estimates, however, were weighted to account for nonresponse, and this may mitigate this bias. In addition, the overall sociodemographic characteristics of our sample were similar to those reported in 2016 US census data. 61 We did not consider race/ethnicity or state of residence in our analyses because of inadequate sample sizes. The strengths of our study include the use of nationally representative and provider-verified data for the receipt of HPVV.
In conclusion, we estimated that an additional 6.77 million girls and an additional 7.62 million boys aged 11 to 12 years would need to receive 2 doses of the vaccine between 2018 and 2026 for 80% prevalence to be achieved by 2026. Most adolescents (11-12 years old) would also need to initiate HPVV, and this highlights the importance of efforts targeted at commencing vaccination in this age group. Reaching this large number of girls and boys has the potential to prevent deaths from several cancers. Broad implementation of the vaccine through innovative strategies for improving physician recommendations, parental acceptance, and access to care is necessary to achieve this goal.
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